Prematüre retinopatisi: Bir yıllık sonuçlarımız

Prematüre retinopatisi iyi takip ve tedavi edilmediğinde önemli bir halk sağlığı sorunu olarak karşımıza çıkmak-tadır. Klasik tedavi yöntemleri kriyo veya lazer ile ablas-yondur. Araştırmamızın amacı anabilim dalımızda takip ve tedavi ettiğimiz prematüre çocukların 1 yıllık sonuçla-rını değerlendirmekti. Nisan 2003-Mart 2004 tarihleri arasında muayene edilen 129 prematürenin 258 gözü değerlendirmeye alındı. Çalışmaya kabul kriteri olarak doğum haftasının 36 haftadan düşük olması (26-36 ortalama 31,5) ve doğum ağırlığının 2500 gramdan az olması (794-2300 gr, ortalama 1442 gr) esas alındı. Toplam 36 gözde (%13,9) değişik evrelerde prematüre retinopatisi tespit edildi; 15 gözde (%5,8) evre I, 6 gözde (%2,3) evre II, 14 gözde (%5,4) evre III, 1 gözde (%0,3) evre IV B prematüre retinopatisi tespit edildi. Evre I-II de %80 spontan regresyon tespit edilirken evre III de bu oran %7 olarak bulundu. Ülkemizde tüm prematüreler için oftalmolojik muayene yapılamamasına rağmen, prematüre retinopatisi prevalansında önemli artış tespit edilemedi.

etinopathy of prematurity : One our year results

Unless retinopathy of prematurity is given medical intensive and regular care, it would emerge as a major public health problem. Classical methods of treatment are laser ablation and cryotherapy. The goal of our research was to examine 1-year results of the premature children that we followed and treated in our clinic. 258 eyes of 129 premature, being treated between April 2003 and March 2004, were evaluated. It is accepted as admission criteria that birth week is lower than 36 weeks (26-36 average 31.5) and birth weight is less than 2500 grams (794-2300 grams, the average 1442 g). Different phases of retinopathy of prematurity were observed in total of 36 eyes (13.9%); phase I in 15 eyes (5.8%); phase II in 6 eyes (2,3%); phase III in 14 eyes (5,4%); phase IV B in 1 eye (0,3%) were detected. While spontaneous regression was ascertain in phase I-II retinopathy of prematurity with 80%, the rate of was found as 7% in phase III. Despite eye examination for all prematures are not performed in our country, serious increase in retinopathy of prematurity prevalence was not detected.

PDF

___

1. Reynold JD. Retinopathy of prematurity. In Olitsky SE, Nelson LB eds. Pediatric Ophtalmology Pheldelphia: W.B Saunders Co, 1991; v.9 chap 21: 303-9.
2. Palmer EA, Flayn JT,Hardly RJ. Incidance and course retinopathy of prematurity. Ophtalmology 1991;98: 1628-40.
3. Stone J, Chan-ling T, Peter J, Itin A, Gnessin H, Keshet E. Roles of vasküler endothelial growth factor and astocyt degeneration in the genesis of retinopathy of prematurity. Invest Ophtalmo Vis Sci 1996;37: 290-9.
4. Reynolds JD. The manegement of retinopathy of prematurity. Pediatric Drugs 2001;3: 263-72.
5. Laskhari K, Hirose T, Yazdany J, Meckmel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor are differantially elevated in patients with advanced retinopathy of prematurity. Am J Pathology 2000;156: 1337-44.
6. Chiang MF, Arons RR, Flayn JT, Starren JB. Incidence of prematurityof retinopathy of prematurity from 1996 to 2000; analysis of a compherensive newyork state patient database. Ophtalmology 2004;111: 1317-25.
7. Simons BD, Flyn JT, Retinopathy of prematurity and associated factors. International Ophtalmology Clinics 1999;39: 29-48.
8. Cryotherapy for retinopathy of prematurity cooperative group, multicenter trial of cryotherapy of prematurity. Preliminary Results. Arch Ophtalmol 1998;106: 471-9.
9. Higgins RD, Mandelsohn AL, DeFoe MJ, Ucsel R, Handricks-Munoz KD. Antenatal dexamethasone and decreased severity of retinopathy of prematurity. Arch Ophtalmology 1998; 116:601-5.
10. Hussain N, Clive J, Bahandari V. Current incidence of retinopathy of prematurity 1989-1997. Pediatrics 1999;104: e26.